Cargando…
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase
INTRODUCTION: The impact of COVID-19 pandemic represents a serious challenge for ‘frail’ patients' populations with inflammatory autoimmune systemic diseases such as systemic sclerosis (SSc). We investigated the prevalence and severity of COVID-19, as well the effects of COVID-19 vaccination ca...
Ejemplares similares
-
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study
por: Ferri, Clodoveo, et al.
Publicado: (2021) -
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
por: Ferri, Clodoveo, et al.
Publicado: (2020) -
Systemic Sclerosis Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide
por: Borghini, Annalisa, et al.
Publicado: (2015) -
Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022) -
Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022)